SHH/SMO inhibitors have been shown to inhibit the CSCs of some cancers, including pancreatic cancer (ALDH+ cells), colon cancer (CD133+ cells), breast cancer (CD44 +CD24− cells) and gastric cancer (CD44+ cells) [143,144,145,146]. This evidence concerns the gene SMO and pancreatic neoplasm.